ALS Association: The Lawrence and Isabel Barnett Drug Development Program (LOI)
| Name: |
ALS Association: The Lawrence and Isabel Barnett Drug Development Program (LOI) Application deadline: 18/12/23 |
|---|---|
| General description: |
Topics of interest: Both novel programs and repurposing of approved or clinically safe therapies from other disease indications are appropriate for this funding opportunity. Especially interested in: • In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapies) in models of ALS. • Studies focused on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement. • Other Investigational New Drug (IND)-enabling studies. Funding: $500,000 in total funding over 2 years https://www.als.org/research/funding-opportunities https://www.als.org/sites/default/files/2023-11/2024-Barnett-RFA.pdf |
| Source: | Foreign |
| Budget: | $250,000/year for 2 years |
| Number of research years: | 2 |
| Contact person: | Robi, 2152, robertg@trdf.technion.ac.il; iris 1272, irisbr@technion.ac.il |
| Fields: | Life Sciences and medicine |
| Type of fund: | The fund is not a competitive fund |
| Related fund and profiles: | ALS Association ,Access available for Technion staff. Please sign in to see the Agency profiles (upper left corner) |